News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
732,767 Results
Type
Article (44640)
Company Profile (311)
Press Release (687814)
Multimedia
Podcasts (107)
Webinars (16)
Section
Business (212526)
Career Advice (2188)
Deals (37144)
Drug Delivery (115)
Drug Development (84351)
Employer Resources (177)
FDA (16803)
Job Trends (15619)
News (360403)
Policy (34534)
Tag
Academia (2636)
Accelerated approval (11)
Adcomms (29)
Allergies (102)
Alliances (52230)
ALS (114)
Alzheimer's disease (1481)
Antibody-drug conjugate (ADC) (173)
Approvals (16787)
Artificial intelligence (340)
Autoimmune disease (34)
Automation (19)
Bankruptcy (378)
Best Places to Work (11845)
BIOSECURE Act (21)
Biosimilars (134)
Biotechnology (193)
Bladder cancer (94)
Brain cancer (38)
Breast cancer (374)
Cancer (2969)
Cardiovascular disease (234)
Career advice (1826)
Career pathing (33)
CAR-T (194)
CDC (34)
Cell therapy (521)
Cervical cancer (22)
Clinical research (69382)
Collaboration (1070)
Company closure (3)
Compensation (706)
Complete response letters (32)
COVID-19 (2722)
CRISPR (64)
C-suite (340)
Cystic fibrosis (116)
Data (3040)
Decentralized trials (2)
Denatured (32)
Depression (67)
Diabetes (362)
Diagnostics (6542)
Digital health (23)
Diversity (10)
Diversity, equity & inclusion (46)
Drug discovery (146)
Drug pricing (145)
Drug shortages (34)
Duchenne muscular dystrophy (129)
Earnings (89628)
Editorial (44)
Employer branding (21)
Employer resources (154)
Events (117909)
Executive appointments (875)
FDA (18493)
Fibrodysplasia Ossificans Progressiva (2)
Friedreich's ataxia (4)
Frontotemporal dementia (9)
Funding (960)
Gene editing (141)
Generative AI (28)
Gene therapy (401)
GLP-1 (880)
Government (4711)
Grass and pollen (5)
Guidances (181)
Healthcare (19182)
HIV (41)
Huntington's disease (31)
IgA nephropathy (43)
Immunology and inflammation (169)
Immuno-oncology (10)
Indications (40)
Infectious disease (2906)
Inflammatory bowel disease (155)
Inflation Reduction Act (10)
Influenza (62)
Intellectual property (122)
Interviews (341)
IPO (17035)
IRA (52)
Job creations (4170)
Job search strategy (1557)
Kidney cancer (14)
Labor market (52)
Layoffs (540)
Leadership (25)
Legal (8556)
Liver cancer (80)
Longevity (12)
Lung cancer (415)
Lymphoma (213)
Machine learning (11)
Management (61)
Manufacturing (420)
MASH (95)
Medical device (13602)
Medtech (13607)
Mergers & acquisitions (20835)
Metabolic disorders (926)
Multiple sclerosis (102)
NASH (20)
Neurodegenerative disease (126)
Neuropsychiatric disorders (38)
Neuroscience (2197)
NextGen: Class of 2025 (6734)
Non-profit (4564)
Now hiring (47)
Obesity (480)
Opinion (263)
Ovarian cancer (103)
Pain (120)
Pancreatic cancer (121)
Parkinson's disease (194)
Partnered (22)
Patents (311)
Patient recruitment (170)
Peanut (54)
People (60229)
Pharmaceutical (98)
Pharmacy benefit managers (25)
Phase I (21629)
Phase II (30483)
Phase III (22814)
Pipeline (1678)
Policy (227)
Postmarket research (2685)
Preclinical (9161)
Press Release (68)
Prostate cancer (145)
Psychedelics (38)
Radiopharmaceuticals (263)
Rare diseases (495)
Real estate (6377)
Recruiting (68)
Regulatory (23873)
Reports (50)
Research institute (2400)
Resumes & cover letters (371)
Rett syndrome (9)
RNA editing (9)
RSV (56)
Schizophrenia (95)
Series A (163)
Series B (112)
Service/supplier (14)
Sickle cell disease (64)
Special edition (21)
Spinal muscular atrophy (154)
Sponsored (33)
Startups (3808)
State (2)
Stomach cancer (16)
Supply chain (82)
Tariffs (65)
The Weekly (73)
Vaccines (820)
Venture capital (55)
Weight loss (315)
Women's health (48)
Worklife (17)
Date
Today (92)
Last 7 days (359)
Last 30 days (1921)
Last 365 days (32097)
2025 (17315)
2024 (36157)
2023 (40937)
2022 (52126)
2021 (56678)
2020 (55113)
2019 (47833)
2018 (36147)
2017 (33582)
2016 (33176)
2015 (39016)
2014 (32966)
2013 (28091)
2012 (30170)
2011 (30876)
2010 (28895)
Location
Africa (811)
Alabama (62)
Alaska (7)
Arizona (253)
Arkansas (14)
Asia (42146)
Australia (6675)
California (7515)
Canada (2386)
China (708)
Colorado (325)
Connecticut (321)
Delaware (197)
Europe (90435)
Florida (1142)
Georgia (248)
Hawaii (1)
Idaho (59)
Illinois (658)
India (28)
Indiana (376)
Iowa (16)
Japan (238)
Kansas (109)
Kentucky (29)
Louisiana (14)
Maine (64)
Maryland (1045)
Massachusetts (5629)
Michigan (248)
Minnesota (455)
Mississippi (3)
Missouri (90)
Montana (28)
Nebraska (25)
Nevada (82)
New Hampshire (66)
New Jersey (2117)
New Mexico (31)
New York (2108)
North Carolina (1136)
North Dakota (8)
Northern California (3297)
Ohio (239)
Oklahoma (16)
Oregon (40)
Pennsylvania (1627)
Puerto Rico (18)
Rhode Island (36)
South America (1186)
South Carolina (35)
South Dakota (1)
Southern California (2806)
Tennessee (127)
Texas (1143)
United States (28044)
Utah (224)
Virginia (197)
Washington D.C. (73)
Washington State (643)
West Virginia (4)
Wisconsin (69)
732,767 Results for "mei pharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
MEI Pharma Reports Third Quarter Fiscal Year 2025 Cash Position
May 14, 2025
·
4 min read
Press Releases
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position
February 12, 2025
·
4 min read
Biotech Beach
MEI Pharma to Present at the Stifel 2024 Virtual Targeted Oncology Forum
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today announced that David Urso, president and chief executive officer of MEI Pharma, will participate in a fireside chat at the Stifel 2024 Virtual Targeted Oncology Forum on Tuesday, April 16 at 1:30 PM Eastern Time.
April 10, 2024
·
3 min read
Business
MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma, Inc., a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, reported results for the three and nine months ended March 31, 2024, and highlighted recent corporate events.
May 9, 2024
·
12 min read
Drug Development
MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344
MEI Pharma, Inc. today reported that the Company’s Board of Directors unanimously agreed on a strategic plan to leverage recent positive voruciclib and ME-344 clinical data to prioritize clinical development of voruciclib while enabling development of a new ME-344 formulation for Phase 1 study.
April 11, 2024
·
11 min read
Biotech Beach
MEI Pharma to Present at the Stifel 2023 Healthcare Conference
MEI Pharma, Inc. today announced it will participate in the Stifel 2023 Healthcare Conference.
November 8, 2023
·
3 min read
Press Releases
MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position
November 12, 2024
·
4 min read
Business
MEI Pharma Reports Second Quarter Fiscal Year 2024 Results and Operational Highlights
MEI Pharma, Inc. (Nasdaq: MEIP), a clinical-stage pharmaceutical company evaluating novel drug candidates to address known resistance mechanisms to standard-of-care cancer therapies, today reported results for the three and six months ended December 31, 2023, and highlighted recent corporate events.
February 13, 2024
·
9 min read
Drug Development
MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients
MEI Pharma, Inc. today reported that 25% of evaluable patients with relapsed metastatic colorectal cancer (“mCRC”) in Cohort 1 of the ongoing Phase 1b study evaluating ME-344, an investigational inhibitor of mitochondrial oxidative phosphorylation (“OXPHOS”), in combination with bevacizumab (Avastin®) had no disease progression at Week 16.
April 11, 2024
·
10 min read
Biotech Beach
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023
MEI Pharma, Inc. will be presented during a poster session at the upcoming 65th American Society of Hematology (ASH) Annual Meeting and Exposition to be held December 9 – 12, 2023.
November 2, 2023
·
6 min read
1 of 73,277
Next